Sera Prognostics Inc Cl A (SERA) Stock Price, Quote & News

Company Profile

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy relate...

Industry: Medical Devices

Sector: Healthcare

Phone: 801 990 0520

Fax: 801 990 6601

Website: www.sera.com

Address:

2749 East Parleys Way, Suite 200, Salt Lake City, United States

ShogunBlade May. 12 at 10:00 AM

$SERA Sera Prognostics focuses on predicting preterm birth risk, a major healthcare problem with high medical costs and neonatal complications.

0 · Reply

StocktwitsEarnings May. 6 at 8:15 PM

$SERA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 15.00% YoY • Reported revenue of $0.01M down -63.16% YoY • Sera Prognostics anticipates meaningful cost savings of approximately $9.6M in 2027, with decreased cash expenses of approximately 35% in R&D and 25% in G&A, expecting existing cash to fund operations through 2029.

0 · Reply

OfficialStocktwitsUser Mar. 20 at 5:43 PM

$SERA RSI: 28.04, MACD: -0.2051 Vol: 0.19, MA20: 2.06, MA50: 2.62 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

mikesterz7 Mar. 18 at 8:23 PM

$SERA 🚨 In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine. Key findings from the Study include: 56% and 32% fewer babies were born before 32 and 35 weeks, respectively 20% fewer babies admitted to the NICU Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A NICU day was saved for every 4.2 patients screened Advanced discussions underway with 10 commercial and Medicaid payers across 13 states for PreTRM program adoption, including the addition of a new partner program, bringing the total to two active partner programs. "2025 marked a pivotal year for Sera as we moved from clinical validation to commercial execution," said Zhenya Lindgardt, Sera's President and Chief Executive Officer.

0 · Reply

StocktwitsEarnings Mar. 18 at 8:13 PM

$SERA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.16 up 36.00% YoY • Reported revenue of $0.01M down -58.33% YoY • Sera Prognostics anticipates continued net losses and negative cash flows for the foreseeable future, but expects its cash runway to last through 2028. Research and development expenses are projected to decrease in 2026, while selling and marketing expenses are expected to increase.

0 · Reply

Fettenajs2026 Mar. 18 at 6:11 PM

$SERA

0 · Reply

topstockalerts Mar. 13 at 1:17 PM

Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD

0 · Reply

topstockalerts Mar. 13 at 11:39 AM

Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD

0 · Reply

prismmarketview Mar. 11 at 4:45 PM

PRISM Mid-Day Movers: Beauty & Wellness and Pharmaceuticals are Today’s Leaders. The Beachbody Company (NASDAQ: $BODI) is jumping ~32% to $11 on quadruple‑normal volume as traders lean into its cost‑cut turnaround and higher‑margin digital fitness and nutrition subscriptions. KALA BIO (NASDAQ: $KALA) rips 28% to ~$0.38 on an eye‑popping 246M shares traded, a purely momentum‑driven bounce that still leaves this sub‑$10M, loss‑making biotech deep in penny‑stock territory. Other Notable Movers: Ocugen, Inc. ( $OCGN) up 26% Sera Prognostics ( $SERA) up 25% Wearable Devices Ltd. ( $WLDS) down -17% https://prismmarketview.com/prism-mid-day-movers-beauty-wellness-and-pharmaceuticals-are-todays-leaders/

0 · Reply

BillionerOfKing Feb. 18 at 4:47 PM

$SERA Current Stock Price: $2.57 Contracts to trade: $2.5 SERA Feb 20 2026 Call Entry: $0.27 Exit: $0.41 ROI: 52% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Sera Prognostics reports Q1 EPS (17c), consensus (17c)

May 6, 2026, 5:00 PM EDT - 6 days ago

Sera Prognostics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:05 PM EDT - 6 days ago

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Apr 22, 2026, 8:05 AM EDT - 21 days ago

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Mar 18, 2026, 5:00 PM EDT - 7 weeks ago

Sera Prognostics Earnings Call Transcript: Q4 2025

2026-03-18T20:11:17.000Z - 7 weeks ago

Sera Prognostics reports Q4 EPS (16c), consensus (19c)

Mar 18, 2026, 4:05 PM EDT - 7 weeks ago

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Mar 4, 2026, 8:05 AM EST - 2 months ago

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

Mar 2, 2026, 1:10 PM EST - 2 months ago

Sera Prognostics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 17, 2026, 8:05 AM EST - 3 months ago

SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE

2025-12-14T17:35:07.000Z - 5 months ago

Sera Prognostics initiated with a Buy at Jefferies

2025-11-24T13:10:59.000Z - 6 months ago

Sera Prognostics announces publication acceptance for PRIME study

Nov 24, 2025, 8:00 AM EST - 6 months ago

Sera Announces Publication Acceptance for PRIME Study

Nov 13, 2025, 5:00 PM EST - 6 months ago

Sera Prognostics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Oct 30, 2025, 4:05 PM EDT - 6 months ago

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 13, 2025

Oct 1, 2025, 8:05 AM EDT - 8 months ago

Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Sera Prognostics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:05 AM EDT - 9 months ago

SERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

Aug 6, 2025, 5:00 PM EDT - 9 months ago

Sera Prognostics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 9 months ago

SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Jul 29, 2025, 4:05 PM EDT - 10 months ago

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025

May 29, 2025, 8:30 AM EDT - 1 year ago

SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

May 21, 2025, 9:30 AM EDT - 1 year ago

Sera Prognostics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

2025-05-08T20:48:41.000Z - 1 year ago

Sera Prognostics names Lee Anderson as Chief Commercial Officer

May 8, 2025, 4:40 PM EDT - 1 year ago

SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

May 7, 2025, 5:00 PM EDT - 1 year ago

Sera Prognostics Earnings Call Transcript: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

Mar 19, 2025, 5:00 PM EDT - 1 year ago

Sera Prognostics Earnings Call Transcript: Q4 2024

2025-03-19T20:15:55.000Z - 1 year ago

Sera Prognostics appoints Jeff Elliott to Board, two members stepping down

2025-03-19T20:11:42.000Z - 1 year ago

Sera Prognostics reports Q4 EPS (25c) vs. (25c) last year

Mar 19, 2025, 4:10 PM EDT - 1 year ago

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

Mar 19, 2025, 4:05 PM EDT - 1 year ago

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Mar 5, 2025, 9:50 AM EST - 1 year ago

Sera Prognostics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 21, 2025, 8:30 AM EST - 1 year ago

Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

2025-02-11T11:15:54.000Z - 1 year ago

Sera Prognostics announces pricing of $50M public offering

Feb 10, 2025, 10:41 PM EST - 1 year ago

Sera Prognostics Announces Pricing of $50 Million Public Offering

2025-02-10T21:11:44.000Z - 1 year ago

Sera Prognostics announces Class A common stock offering

Feb 10, 2025, 4:01 PM EST - 1 year ago

Sera Prognostics Announces Proposed Public Offering

Jan 31, 2025, 5:00 PM EST - 1 year ago

Sera Prognostics Transcript: R&D Day 2025

Jan 27, 2025, 5:02 PM EST - 1 year ago

Sera Prognostics to Host Virtual R&D Day on January 31

Jan 16, 2025, 12:45 PM EST - 1 year ago

Sera Prognostics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 8:30 AM EST - 1 year ago

Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 2:30 PM EST - 1 year ago

Sera Prognostics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 4:01 PM EST - 1 year ago

Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting

Dec 2, 2024, 8:30 AM EST - 1 year ago

Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Nov 6, 2024, 5:00 PM EST - 1 year ago

Sera Prognostics Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024

Sep 11, 2024, 10:00 AM EDT - 1 year ago

Sera Prognostics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 4:53 PM EDT - 1 year ago

Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 11:00 AM EDT - 1 year ago

Sera Prognostics Transcript: UBS Genomic Medicine Conference

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024

2024-08-07T21:19:52.000Z - 1 year ago

Sera Prognostics files $100M mixed securities shelf

Aug 7, 2024, 5:00 PM EDT - 1 year ago

Sera Prognostics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

2024-08-05T13:35:30.000Z - 1 year ago

Sera Prognostics Inc trading resumes

2024-08-05T13:30:27.000Z - 1 year ago

Sera Prognostics Inc trading halted, volatility trading pause

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024

2024-07-09T12:35:08.000Z - 2 years ago

Sera Prognostics’ PreTRM test reduces neonatal morbidity, mortality by 18%

Jul 9, 2024, 8:30 AM EDT - 2 years ago

Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial

2024-07-01T12:32:05.000Z - 2 years ago

Sera Prognostics added to Russell 2000, Russell 3000 Indexes

Jul 1, 2024, 8:30 AM EDT - 2 years ago

SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION

2024-05-28T12:37:30.000Z - 2 years ago

Sera Prognostics set to be added to Russell 2000, 3000 indexes

May 28, 2024, 8:30 AM EDT - 2 years ago

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

May 8, 2024, 5:00 PM EDT - 2 years ago

Sera Prognostics Earnings Call Transcript: Q1 2024

May 8, 2024, 4:05 PM EDT - 2 years ago

SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 29, 2024, 2:15 PM EDT - 2 years ago

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024

2024-04-24T12:31:01.000Z - 2 years ago

Four new option listings and one option delisting on April 24th

FSBC SBIT

Mar 20, 2024, 5:00 PM EDT - 2 years ago

Sera Prognostics Earnings Call Transcript: Q4 2023

2024-03-20T20:08:19.000Z - 2 years ago

Sera Prognostics reports Q4 EPS (25c) vs. (31c) last year

Mar 20, 2024, 4:05 PM EDT - 2 years ago

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS

Mar 4, 2024, 8:30 AM EST - 2 years ago

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Feb 29, 2024, 11:14 AM EST - 2 years ago

Sera Prognostics To Present at TD Cowen 44th Annual Healthcare Conference

2023-12-06T13:36:21.000Z - 2 years ago

Sera Prognostics halts PRIME study enrollment due to reaching efficacy endpoint

Dec 6, 2023, 8:30 AM EST - 2 years ago

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Nov 22, 2023, 1:00 PM EST - 2 years ago

SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

Nov 8, 2023, 5:00 PM EST - 2 years ago

Sera Prognostics Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:05 PM EST - 2 years ago

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023

Sep 21, 2023, 8:30 AM EDT - 2 years ago

SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023

Aug 9, 2023, 5:00 PM EDT - 2 years ago

Sera Prognostics Earnings Call Transcript: Q2 2023

Aug 9, 2023, 4:05 PM EDT - 2 years ago

SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

Jul 31, 2023, 8:30 AM EDT - 3 years ago

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023

May 25, 2023, 4:15 PM EDT - 3 years ago

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

ShogunBlade May. 12 at 10:00 AM

$SERA Sera Prognostics focuses on predicting preterm birth risk, a major healthcare problem with high medical costs and neonatal complications.

0 · Reply

StocktwitsEarnings May. 6 at 8:15 PM

0 · Reply

OfficialStocktwitsUser Mar. 20 at 5:43 PM

0 · Reply

mikesterz7 Mar. 18 at 8:23 PM

0 · Reply

StocktwitsEarnings Mar. 18 at 8:13 PM

0 · Reply

Fettenajs2026 Mar. 18 at 6:11 PM

$SERA

0 · Reply

topstockalerts Mar. 13 at 1:17 PM

Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD

0 · Reply

topstockalerts Mar. 13 at 11:39 AM

Pre Market Top Gainers PT2 $SERA $VEEE $ADTX $EEIQ $HKPD

0 · Reply

prismmarketview Mar. 11 at 4:45 PM

0 · Reply

BillionerOfKing Feb. 18 at 4:47 PM

0 · Reply

OfficialStocktwitsUser Jan. 25 at 1:20 AM

$SERA RSI: 56.78, MACD: 0.0441 Vol: 0.26, MA20: 3.37, MA50: 3.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DARKP00L Jan. 7 at 1:55 PM

$SERA 08:40 on Jan. 07 2026 Sera Prognostics Announces Randomized Trial Finds PreTRM Test Improves Outcomes By Identifying Women At Risk For Preterm Birth #tradeideas

0 · Reply

OfficialStocktwitsUser Dec. 26 at 5:28 PM

$SERA RSI: 76.84, MACD: 0.1233 Vol: 0.24, MA20: 3.35, MA50: 3.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

CalypsoCalls Dec. 25 at 8:48 AM

$SERA Strategic positioning matters less than consistent throughput, because growth without leverage now attracts skepticism. Absent traction, patience will erode.

0 · Reply

SuperGreenToday Dec. 23 at 10:02 PM

$SERA Share Price: $3.59 Contract Selected: Jan 15, 2027 $2.5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.43 – $1.75 Potential Upside: 59% ROI Time to Expiration: 387 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

notreload_ai Dec. 15 at 4:13 PM

Jefferies starts coverage of $SERA with a Buy rating, highlighting its PreTRM test for predicting preterm birth and $1.6B U.S. market potential. https://notreload.xyz/jefferies-gives-buy-rating-to-sera-prognostics/

0 · Reply

quodo Dec. 15 at 2:25 PM

$SMTI $CMMB $SERA $NTHI Most small caps are still trying to survive 2026. $CAPS is already planning how to compound through it. $100M run-rate reaffirmed. Margins expanding. Execution > speculation.

0 · Reply

Goldwave9 Nov. 27 at 4:19 PM

$SERA this will be a big big mover, but not necessarily in five minutes. Give it some time.

0 · Reply

d_risk Nov. 13 at 10:08 PM

$SERA - Sera Prognostics Inc. Class A Common Stock - 10Q - Updated Risk Factors SERA’s latest 10-Q risk factors spotlight new dependencies on third-party specimen collection, expanded cost and capital needs, heightened PreTRM test commercialization hurdles, major elaboration on supply chain, cybersecurity, and AI risks, removal of data privacy and healthcare compliance disclosures, and added warnings on analyst coverage, anti-takeover provisions, and exclusive forum clauses—reflecting broader operational, financial, and regulatory uncertainties. #HealthcareDiagnostics #RegulatoryCompliance #AIRisk #Cybersecurity #SupplyChainRisk 🟢 Added 🟠 Removed https://d-risk.ai/SERA/10-Q/2025-11-13

0 · Reply

kshonstocks Oct. 27 at 2:23 PM

$SERA from scans, has the higher highs

0 · Reply

Market Cap	67.72M
Revenue (ttm)	80,000.00
Net Income (ttm)	-31.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39,912.50%
Debt to Equity Ratio	0.00

Volume	77,300
Avg Vol	62,084
Day's Range	N/A - N/A
Shares Out	39.14M
Stochastic %K	13%
Beta	0.92
Analysts	Strong Sell
Price Target	$5.00